| Literature DB >> 19669264 |
Zuojiong Gong1, Shaonan Yan, Ping Zhang, Yanqing Huang, Luwen Wang.
Abstract
BACKGROUND: Hyperhomocysteinemia is implicated in the pathogenesis of various liver diseases. In this study, the effects of S-adenosylmethionine (SAM) on hyperhomocysteinemia and steatosis with ethanol-induced liver injury in rats were examined and their mechanisms were explored.Entities:
Year: 2008 PMID: 19669264 PMCID: PMC2716886 DOI: 10.1007/s12072-008-9082-1
Source DB: PubMed Journal: Hepatol Int ISSN: 1936-0533 Impact factor: 6.047
Fig. 1Histological examinations of the liver: (a) normal group, (b) model group, (c) low-dose SAM group, and (d) high-dose SAM group. Magnification, 200×
Liver necroinflammatory scores and steatosis scores
| Groups | Inflammation scores | Necrosis scores | Steatosis necrosis | |
|---|---|---|---|---|
| Normal control | 12 | 0.224 ± 0.115a | 0.061 ± 0.043a | 0.304 ± 0.056a |
| Model | 12 | 2.963 ± 0.393 | 0.989 ± 0.254 | 3.372 ± 0.237 |
| Low-dose SAM | 12 | 0.331 ± 0.123a | 0.074 ± 0.026a | 0.351 ± 0.032a |
| High-dose SAM | 12 | 0.301 ± 0.227a | 0.069 ± 0.135a | 0.346 ± 0.106a |
aCompared with model group, P < 0.01
bCompared with model group, P < 0.05
SAM, S-adenosylmethionine
Detections of plasma tHcy, liver function, and blood fat levels
| Groups | tHcy (mmol l−1) | ALT (U l−1) | AST (U l−1) | TC (mmol l−1) | TG (mmol l−1) | |
|---|---|---|---|---|---|---|
| Normal control | 12 | 11.36 ± 1.27a | 57.18 ± 1.99a | 215.56 ± 1.59a | 2.22 ± 0.25a | 0.35 ± 0.49a |
| Model | 12 | 24.64 ± 2.47 | 157.62 ± 2.29 | 247.78 ± 1.93 | 15.61 ± 0.36 | 2.4 ± 0.18 |
| Low-dose SAM | 12 | 23.30 ± 3.34c | 64.35 ± 1.62a | 189.39 ± 6.45a | 3.53 ± 0.29a | 0.57 ± 0.20a |
| High-dose SAM | 12 | 22.45 ± 2.66c | 63.75 ± 2.85a | 187.50 ± 5.54a | 3.49 ± 0.32a | 0.54 ± 0.31a |
aCompared with model group, P < 0.01
bCompared with model group, P < 0.05
cCompared with model group, P > 0.05
ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAM, S-adenosylmethionine; tHyc, total homocysteine; TC, total cholesterol; TG, triglyceride
Detection of TNF-α, TGF-β1, MDA, and GSH
| Groups | TNF-α (pg ml−1) | TGF-β1 (pg ml−1) | MDA (nmol mg−1 protein) | GSH (mg mg−1 protein) | |
|---|---|---|---|---|---|
| Normal control | 12 | 3.84 ± 0.12a | 20.45 ± 1.36a | 2.82 ± 0.16a | 26.87 ± 2.33a |
| Model | 12 | 4.67 ± 0.19 | 26.39 ± 1.21 | 6.69 ± 0.34 | 11.38 ± 1.98 |
| Low-dose SAM | 12 | 4.19 ± 0.40b | 25.09 ± 0.83b | 1.65 ± 0.51a | 19.50 ± 1.77a |
| High-dose SAM | 12 | 4.05 ± 0.58b | 24.46 ± 0.50b | 1.63 ± 0.17a | 20.47 ± 0.85a |
aCompared with model group, P < 0.01
bCompared with model group, P < 0.05
GSH, glutathione; MDA, malondialdehyde; SAM, S-adenosylmethionine; TGF-β1, transforming growth factor β1; TNF-α, tumor necrosis factor α
Fig. 2RT-PCR analysis of expressions of TNF-α mRNA and TGF-β1 mRNA. (a) TNF-α mRNA, (b) GAPDH mRNA, (c) TGF-ß1 mRNA, (d) GAPDH mRNA. Lane 1 represents normal group, lane 2 represents model group, lane 3 represents low-dose SAM group, and lane 4 represents high-dose SAM group. M represents molecular size marker